Dear valued friends and customers, Warm wishes for the upcoming Year of the Horse! Our team will be taking a break to celebrate the Spring Festival with our families from February 14th to February 23rd. During this period, responses to inquiries and orders may be delayed. We will resume normal ...
Pharmacology and Synthesis of Ruxolitinib Pharmacology Ruxolitinib is a potent inhibitor of Janus-associated kinases (JAK) 1 and 2, which play crucial roles in the signaling pathways for various cytokines and growth factors involved in hematopoiesis and immune function. The dysregulation of JAK-STAT ...
CPHI & PMEC China is Asia’s leading pharmaceutical show for trading, knowledge sharing and networking. It spans all industry sectors along the pharmaceutical supply chain and is your one-stop platform to grow business in the 2nd largest pharma market in the world. CPHI & PMEC China 2024, with the co...
Apixaban is a novel oral anticoagulant. It is possible to directly, reversibly, and highly selectively block the active site of factor Xa, blocking the conversion of prothrombin to thrombin, and thereby preventing thrombosis. As compared with rivaroxaban, apixaban also prevents thrombosis by ...
On 6 Aprile 2024, Novo Nordisk published the result of STEP HFpEF DM on the New England Journal of Medicine. The results demonstrated that among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide led to larger reductions in heart failure...
API China focuses on improving the overall level of production, research and development of pharmaceutical raw materials, intermediates and pharmaceutical excipient in China, representing new products and technologies in China's pharmaceutical industry. API China has become a brand event that brings ...
As an important class of hypoglycemic and weight loss drugs, GLP-1 drugs have attracted much attention and made significant development in recent years. Since GLP-1 drugs were found to have hypoglycemic effects, GLP-1 targets have been firmly in the hot track, especially after the approval of ...
Top 30 Anti-tumor Drugs in 2023 (In billion dollars) No. Drug name Company Main indications Sales Growth rate 1 Keytruda (pembrolizumab) MSD Melanoma, NSCLC, Bladder cancer, HNC 25.01 19.5% 2 Opdivo (nivolumab) BMS/ONO Melanoma, NSCLC, HNC 10.04 9.0% 3 Darzalex (daratumumab) Johnson & Johnson ...
On 8 March, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. The FDA decision is based on the results ...
Leave a Message
We will call you back soon!
Your message must be between 20-3,000 characters!
Please check your E-mail!
More information facilitates better communication.
Submitted successfully!
